AGMB — Agomab Therapeutics NV Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Agomab Therapeutics NV, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -8.14 | -11.4 | -46.3 |
| Depreciation | |||
| Deferred Taxes | |||
| Non-Cash Items | -9.62 | -17 | -0.683 |
| Other Non-Cash Items | |||
| Changes in Working Capital | 1.44 | 4.34 | -0.189 |
| Change in Other Assets | |||
| Change in Accounts Payable | |||
| Change in Other Liabilities | |||
| Other Operating Cash Flow | |||
| Cash from Operating Activities | -19 | -24.6 | -46.8 |
| Capital Expenditures | — | — | -0.675 |
| Purchase of Fixed Assets | |||
| Other Investing Cash Flow Items | -44.6 | 40 | 0 |
| Acquisition of Business | |||
| Sale of Business | |||
| Change in Net Investments | |||
| Purchase of Investments | |||
| Cash from Investing Activities | -44.6 | 40 | -0.675 |
| Financing Cash Flow Items | -0.171 | -0.447 | -0.13 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Stock | |||
| Net Issuance / Retirement of Debt | |||
| Cash from Financing Activities | 37.6 | 79.3 | 96.8 |
| Foreign Exchange Effects | |||
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | -25.9 | 94.7 | 49.1 |